C Met Non-Small Cell Lung Cancer Pipeline Analysis Report 2025

C-MET is a subtype of non-small cell lung cancer (NSCLC). It is linked to changes in the MET gene, which codes for a receptor tyrosine kinase. Tumor growth, metastasis, and resistance to specific treatments can result from these alterations. To help patients with this aggressive type of lung cancer, targeted treatments including MET inhibitors are under development. The C Met non-small cell lung cancer pipeline analysis by Expert Market Research focuses on various treatment options for this disease.

Report Coverage

The C Met Non-Small Cell Lung Cancer Pipeline Insight Report by Expert Market Research gives comprehensive insights into C Met non-small cell lung cancer currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for C Met Non-Small Cell Lung Cancer therapeutics. The C Met non-small cell lung cancer report assessment includes the analysis of over 15 pipeline drugs and 10+ companies. The C Met non-small cell lung cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with C Met non-small cell lung cancer treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to C Met non-small cell lung cancer.

C Met Non-Small Cell Lung Cancer Pipeline Outlook

In c-MET non-small cell lung cancer (NSCLC), the MET signaling system, which typically controls cell proliferation, survival, and motility, is dysregulated. Uncontrolled proliferation, invasion, angiogenesis, and metastasis result from aberrant activation caused by overexpression, amplification, or alterations such MET exon 14 skipping. Resistance to treatments that target other pathways, such as EGFR, may also be fueled by these changes. One important oncogenic factor in certain NSCLC subtypes is MET dysregulation.

Therapy for c-MET Tyrosine kinase inhibitors (TKIs), such as tepotinib, capmatinib, and savolitinib, are effective against MET exon 14 skipping mutations, and are used to treat MET changes in non-small cell lung cancer (NSCLC). Even in cases when there are brain metastases, these medications improve outcomes, such as tumor response and disease control rates. Antibody-drug conjugates and monoclonal antibodies are further strategies. Research on combination treatments and methods for overcoming resistance is ongoing.

C Met Non-Small Cell Lung Cancer Epidemiology

The overexpression of C-MET in non-small cell lung cancer (NSCLC) varies greatly among populations and detection techniques. According to studies, prevalence percentages vary from 15% to 70%, depending on thresholds and antibody assays. 68% of NSCLC patients in a sizable Chinese cohort had positive C-MET expression (IHC 2+ or 3+). Moreover, MET amplification is less frequent, happening in only 3.7% of cases. These results demonstrate how important MET changes are in NSCLC.

C Met Non-Small Cell Lung Cancer - Pipeline Therapeutic Assessment

This section of the report covers the analysis of C Met non-small cell lung cancer drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Gene therapies
• Bispecific antibodies
• Immunotherapies
• Monoclonal antibodies
• Small molecules

By Route of Administration

• Oral
• Parenteral
• Others

C Met Non-Small Cell Lung Cancer - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total C Met non-small cell lung cancer clinical trials.

In the C Met non-small cell lung cancer pipeline, 75% of candidates are in Phase II with the largest share while the remaining 25% of the candidates are in Phase I. Thus, demonstrating division of candidates between the two phases and diverse progress toward potential treatments.

C Met Non-Small Cell Lung Cancer - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the C Met non-small cell lung cancer pipeline analysis include gene therapies, bispecific antibodies, immunotherapies, monoclonal antibodies and small molecules. The C Met non-small cell lung cancer report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for C Met non-small cell lung cancer.

C Met Non-Small Cell Lung Cancer Clinical Trials - Key Players

The report for the C Met non-small cell lung cancer pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in C Met non-small cell lung cancer clinical trials:

• AbbVie
• Janssen Research & Development, LLC
• Beijing Pearl Biotechnology Limited Liability Company

C Met Non-Small Cell Lung Cancer - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for C Met non-small cell lung cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of C Met non-small cell lung cancer drug candidates.

Drug: ​Telisotuzumab vedotin

​ AbbVie created the experimental antibody-drug combination, known as Telisotuzumab Vedotin (Teliso-V) to treat non-small cell lung cancer (NSCLC) that overexpresses the c-Met protein. Teliso-V showed an overall response rate of 35% in patients with c-Met High and 23% in individuals with c-Met intermediate in the Phase 2 LUMINOSITY trial. In January 2022, the U.S. FDA designated it as a Breakthrough Therapy, and in September 2024, AbbVie filed a Biologics License Application for the drug.

Drug: Amivantamab

Janssen Research & Development, LLC created the bispecific antibody amivantamab, which targets both the EGFR and MET receptors. It prevents downstream signaling pathways and receptor activation brought on by ligands. In May 2021, the U.S. FDA gave it expedited approval to treat advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Phase 1 of the ongoing clinical trial is assessing the medication's safety, effectiveness, and ideal dosage.

Key Questions Answered in the C Met Non-Small Cell Lung Cancer Pipeline Analysis Report

• Which companies/institutions are leading the C Met non-small cell lung cancer drug development?
• What is the efficacy and safety profile of C Met non-small cell lung cancer pipeline drugs?
• Which company is leading the C Met non-small cell lung cancer pipeline development activities?
• What is the current C Met non-small cell lung cancer commercial assessment?
• What are the opportunities and challenges present in the C Met non-small cell lung cancer pipeline landscape?
• What is the efficacy and safety profile of C Met non-small cell lung cancer pipeline drugs?
• Which company is conducting major trials for C Met non-small cell lung cancer drugs?
• Which companies/institutions are involved in C Met non-small cell lung cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in C Met non-small cell lung cancer?

This product will be delivered within 3-5 business days.